<database>
  <name>massive</name>
  <description>The Massive Database contains information about all the proteomics/metabolomics datasets in massive</description>
  <release>1.0</release>
  <release_date>15-11-10</release_date>
  <entry_count>1</entry_count>
  <entries>
    <entry id="MSV000079017">
      <name>Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells</name>
      <description>Kr√∂nke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M, Svinkina T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Science 2014, 343, 301-305. doi:10.1126/science.1244851.
Lenalidomide is a drug with clinical efficacy in multiple myeloma and other B cell neoplasms, but its mechanism of action is unknown. Using quantitative proteomics, we found that lenalidomide causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. IKZF1 and IKZF3 are essential transcription factors in multiple myeloma. A single amino acid substitution of IKZF3 conferred resistance to lenalidomide-induced degradation and rescued lenalidomide-induced inhibition of cell growth. Similarly, we found that lenalidomide-induced interleukin-2 production in T cells is due to depletion of IKZF1 and IKZF3. These findings reveal a previously unknown mechanism of action for a therapeutic agent: alteration of the activity of an E3 ubiquitin ligase, leading to selective degradation of specific targets.</description>
      <cross_references>
        <ref dbkey="9606" dbname="TAXONOMY"/>
        <ref dbkey="24292625" dbname="pubmed"/>
      </cross_references>
      <dates>
        <date type="submission" value="15-01-26"/>
      </dates>
      <additional_fields>
        <field name="omics_type">Proteomics</field>
        <field name="full_dataset_link">http://massive.ucsd.edu/ProteoSAFe/result.jsp?task=b626b7994f214c69b7eb5d1bddbf5be9&amp;view=advanced_view</field>
        <field name="repository">massive</field>
        <field name="instrument_platform">Q Exactive</field>
        <field name="modification">A protein modification that crosslinks the N6-amino of a peptidyl lysine with the carboxyl of glycylglycine, the two glycine residues left after tryptic digestion of ubiquitin.</field>
        <field name="technology_type">Not available</field>
        <field name="curator_keywords">lenalidomide</field>
        <field name="curator_keywords">ubiquitin</field>
        <field name="submitter">Steven A. Carr</field>
      </additional_fields>
    </entry>
  </entries>
</database>
